Citigroup Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Posted by Max Byerly on Aug 3rd, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lowered by research analysts at Citigroup from $380.00 to $340.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would indicate a potential upside of 56.93% from the company’s current price.

A number of other research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday. Chardan Capital reissued a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a report on Monday. HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, Wells Fargo & Company dropped their price objective on Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating for the company in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $402.67.

Get Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $11.14 during trading on Monday, reaching $216.66. 1,997,354 shares of the company’s stock were exchanged, compared to its average volume of 1,386,364. The company’s fifty day moving average price is $287.96 and its 200-day moving average price is $310.90. Alnylam Pharmaceuticals has a 1-year low of $197.81 and a 1-year high of $495.55. The firm has a market cap of $28.99 billion, a PE ratio of 40.25 and a beta of 0.30. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 104.81%. Alnylam Pharmaceuticals’s revenue was up 96.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.44) EPS. On average, research analysts expect that Alnylam Pharmaceuticals will post 7.22 EPS for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. MV Capital Management Inc. acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth $27,000. Golden State Wealth Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. Finally, Manchester Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Raymond James upgraded ALNY from “outperform” to “strong buy” and set a $420 price target, implying substantial potential upside from recent levels. Finviz analyst upgrade report
Positive Sentiment: Chardan Capital reiterated its “buy” rating, reinforcing the view that Alnylam’s long-term growth prospects remain attractive. Chardan Capital reiterates buy rating
Neutral Sentiment: Barclays lowered its price target from $527 to $450 but retained an “overweight” rating. The reduced target still represents considerable upside, suggesting a more cautious valuation outlook rather than a change to its bullish stance. Benzinga Barclays analyst report
Neutral Sentiment: Wells Fargo, Stifel Nicolaus and Royal Bank of Canada cut their targets to $316, $318 and $350, respectively. These revisions temper expectations but remain above the recent share price. Wells Fargo lowers Alnylam price target Stifel lowers Alnylam price target RBC lowers Alnylam price target
Negative Sentiment: Morgan Stanley lowered its expectations, while Oppenheimer issued a pessimistic forecast. Wall Street Zen also downgraded Alnylam to “hold,” adding to the recent cautious tone around the stock. Morgan Stanley lowers expectations Oppenheimer pessimistic forecast Wall Street Zen downgrades Alnylam

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.